Compare LI & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LI | WST |
|---|---|---|
| Founded | 2015 | 1923 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 17.9B |
| IPO Year | N/A | 2004 |
| Metric | LI | WST |
|---|---|---|
| Price | $17.09 | $241.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $19.07 | ★ $319.43 |
| AVG Volume (30 Days) | ★ 2.7M | 709.3K |
| Earning Date | 03-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.37% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 6.79 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $24.20 | $6.73 |
| Revenue Next Year | $22.91 | $6.07 |
| P/E Ratio | ★ $29.50 | $35.17 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $15.71 | $187.43 |
| 52 Week High | $32.03 | $322.34 |
| Indicator | LI | WST |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 47.85 |
| Support Level | $16.25 | $230.42 |
| Resistance Level | $17.65 | $251.73 |
| Average True Range (ATR) | 0.47 | 6.67 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 27.46 | 44.69 |
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 500,000 NEVs in 2024, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.